Key Takeaways
Rosen Law Firm issued a reminder to ImmunityBio, Inc. (NASDAQ: IBRX) investors about the May 26, 2026, deadline to join a securities class action lawsuit as lead plaintiff.
According to the lawsuit, "defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that... defendant Patrick Soon-Shiong materially overstated Anktiva’s capabilities."
The class period covers purchasers of ImmunityBio securities between January 19, 2026, and March 24, 2026. The lawsuit, first filed by Rosen Law Firm, alleges that these misleading statements caused investors to suffer damages when the true details became public. Another firm, Glancy Prongay Wolke & Rotter LLP, has also announced a similar action.
Investors who purchased IBRX shares during the specified period may be entitled to compensation through a contingency fee arrangement. A lead plaintiff acts on behalf of other class members in directing the litigation, and the deadline to move the Court for this role is May 26.
The lawsuit creates a legal overhang for ImmunityBio, potentially leading to financial liabilities and impacting investor confidence. The outcome of the lead plaintiff selection on May 26 is the next key catalyst in this legal battle.
This article is for informational purposes only and does not constitute investment advice.
